Vivek Ra­maswamy and Matt Gline pen share­hold­er let­ters about the changes now un­der­way at Roivant

Friends and col­leagues,

I am writ­ing to pro­vide our an­nu­al up­date on Roivant. These up­dates are usu­al­ly re­strict­ed to our share­hold­ers, but we are shar­ing this year’s let­ter more broad­ly to an­nounce an up­com­ing change in my role from CEO to Ex­ec­u­tive Chair­man and the pro­mo­tion of Matt Gline to Chief Ex­ec­u­tive Of­fi­cer.

Re­flec­tions on 2020

Much has tran­spired in the world and at our com­pa­ny since my last an­nu­al up­date in Jan­u­ary 2020. One year ago we had just com­plet­ed our $3 bil­lion trans­ac­tion with Sum­it­o­mo Dainip­pon Phar­ma (DSP), and we were eval­u­at­ing how to rein­vest in our busi­ness. At the same time, SARS-CoV-2 was still a dis­tant virus bare­ly on our minds. To­day it has af­flict­ed the en­tire world spar­ing lit­er­al­ly no one from its ef­fects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER